Inactive Instrument

MYOS Corp Stock OTC Bulletin Board

Stocks

US5540511020

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for MYOS Corp

Valuation: MYOS Corp

Market Cap 7.25M 6.37M 5.86M 5.48M 10.28M 684M 10.47M 70.36M 27.25M 337M 27.21M 26.62M 1.17B P/E 2021
-1.04x
P/E 2022 -0.41x
Enterprise Value 2.88M 2.53M 2.33M 2.18M 4.08M 272M 4.16M 27.94M 10.82M 134M 10.81M 10.57M 465M EV / Sales 2021
1.74x
EV / Sales 2022 0.46x
Free-Float
-
Yield 2021 *
-
Yield 2022 -

Financials

2021 2022
Net sales 22.13M 19.44M 17.91M 16.75M 31.41M 2.09B 31.98M 215M 83.23M 1.03B 83.1M 81.28M 3.58B 43.11M 37.87M 34.89M 32.62M 61.18M 4.07B 62.31M 419M 162M 2.01B 162M 158M 6.97B
Net income -43.82M -38.49M -35.46M -33.16M -62.18M -4.13B -63.33M -425M -165M -2.04B -165M -161M -7.08B -47.62M -41.83M -38.54M -36.03M -67.58M -4.49B -68.82M -462M -179M -2.21B -179M -175M -7.7B
Net Debt -7.44M -6.54M -6.02M -5.63M -10.56M -702M -10.76M -72.26M -27.99M -346M -27.95M -27.33M -1.2B -4.37M -3.84M -3.54M -3.31M -6.2M -412M -6.31M -42.42M -16.43M -203M -16.41M -16.05M -706M
Logo MYOS Corp
MYOS RENS Technology Inc. is focused on the discovery, development and commercialization of nutritional ingredients, functional foods, and other technologies for maintaining or improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle-related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin, MYO-T12, a formulation containing Fortetropin. Fortetropin is the Company's all-natural food ingredient clinically shown to enhance muscle size, lean body mass and strength as part of resistance training in humans. Fortetropin is made from fertilized chicken egg yolks using a process that retains the biological integrity and bioactivity of the product.
Employees
-
Sector
-